Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 3/20 | 0.35 |
| ▸ | KDM4B | O94953 | 3/20 | 0.35 |
| ▸ | KDM5C | P41229 | 3/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 3/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL126681 | 0.74 | CSNK2A1 (0.39) | KDM4AKDM4BKDM5CKDM5BKDM4E | |
| SCHEMBL29507176 | 0.74 | PARP1 (0.43) | PARP1KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL127024 | 0.74 | AXL (0.48) | PARP1AURKAKDM4AKDM4BKDM5C | |
| SCHEMBL1664855 | 0.74 | PARP1 (0.43) | PARP1KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL8852431 | 0.74 | BCL2 (0.39) | PARP1KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL29506191 | 0.74 | MAPK1 (0.52) | KDM4AKDM4BKDM5CKDM5BKDM4E | |
| SCHEMBL29424891 | 0.74 | AXL (0.48) | PARP1AURKAKDM4AKDM4BKDM5C | |
| SCHEMBL21912960 | 0.74 | MAPK1 (0.35) | KDM4AKDM4BKDM5CKDM5BKDM4E | |
| SCHEMBL21856245 | 0.74 | MAPK1 (0.52) | KDM4AKDM4BKDM5CKDM5BKDM4E | |
| SCHEMBL5021589 | 0.74 | PARP1 (0.33) | PARP1KDM4AKDM4BKDM5CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4023647-B1 | IMIDAZOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | TSD LIFE SCIENCES CO LTD (KR) | 2025-04-09 | — | — | EP | claimed |
| EP-0538194-B1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA GEIGY AG (CH) | 1997-06-04 | — | — | EP | claimed |
| US-5319080-A | Antiviral agents | CIBA-GEIGY CORPORATION (US) | 1994-06-07 | — | — | US | claimed |
| EP-0538194-A1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | claimed |
| EP-3854799-B1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-11981701-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-05-14 | — | — | US | disclosed |
| EP-3833667-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240067673-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | BGI SHENZHEN (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11873316-B2 | Compositions and methods for phosphoramidite and oligonucleotide synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-16 | — | — | US | disclosed |
| US-20230383277-A1 | COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASE TYPE 1A | BEAM THERAPEUTICS INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-11739325-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-29 | — | — | US | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| EP-0538194-B1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA GEIGY AG (CH) | 1997-06-04 | — | — | EP | disclosed |
| US-5506238-A | HYPOTENSIVE AGENT | EISAI CO., LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| EP-0644196-A1 | TTTr as a protecting group in nucleotide synthesis | CIBA-GEIGY AG (CH) | 1995-03-22 | — | — | EP | disclosed |
| US-5393878-A | Pyrimidine nucleosides having cyclopentafuran skeleton | CIBA-GEIGY CORPORATION (US) | 1995-02-28 | — | — | US | disclosed |
| US-5319080-A | Antiviral agents | CIBA-GEIGY CORPORATION (US) | 1994-06-07 | — | — | US | disclosed |
| US-5268464-A | Process for the preparation of nucleosides | CIBA-GEIGY CORPORATION (US) | 1993-12-07 | — | — | US | disclosed |
| EP-0563010-A2 | Method of preparation of nucleosides | CIBA-GEIGY AG (CH) | 1993-09-29 | — | — | EP | disclosed |
| EP-0538194-A1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | PARP1 211/4885AURKA 944/4885KDM4A 2250/4885 |
| US-11873316-B2 | Compositions and methods for phosphoramidite and oligonucleotide synthesis | RNGTT, POLI, FBL | PARP1 270/4885AURKA 884/4885KDM4A 1699/4885 |
| US-11981701-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | PARP1 319/4885AURKA 517/4885KDM4A 95/4885 |
| US-20230383277-A1 | COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASE TYPE 1A | GDA, GNPDA1, GBA1 | PARP1 1319/4885AURKA 3221/4885KDM4A 1472/4885 |
| US-20240067673-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | NT5C3B, NT5E, NT5C2 | PARP1 417/4885AURKA 783/4885KDM4A 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.